Parkinsonís Institute and Clinical Center Collaborates with Kainos Medicine, Korea for Parkinsonís New Drug Treatment Therapies
Published Friday, June 29, 2018

Parkinson’s Institute and Clinical Center announced today that it is collaborating with Kainos Medicine, Korea on a new drug therapy.
Kainos Medicine recently developed KM-819, which is an innovative new investigational drug based on a novel mode of action that protects dopaminergic neurons from death by inhibiting the function of FAF1 which is known to induce cell death. KM-819 showed efficacy in neuroprotection and inhibiting behavioral impairment induced by MPTP treatment in animals.
Parkinson’s Institute and Clinical Center, who focus on the early detection and complete cure of Parkinson’s are trying to find innovative ways to conquer the disease. “One way to do this is to test novel approaches by analyzing stem cells with unique mutations that may cause Parkinson’s,” says Dr. Carrolee Barlow, CEO, Parkinson’s Institute and Clinical Center.

Read More

Send this page to a friend

Show Other Stories

2500 Hospital Drive, Bldg #10, Suite 1 | Mountain View, CA 94040
650.770.0201 main | 650.770.0204 fax (Clinic Secure)